CD274 and small cell lung carcinoma: SCLC has traditionally been considered a homogeneous disease in terms of therapeutic options, and most clinical research approaches have been borrowed from the management of non-oncogene addicted non-small cell lung cancer (NSCLC); indeed, the current therapy of choice for extensive SCLC is represented by chemotherapy plus an anti-PD-L1 inhibitor.